Asia Pacific Allergy · 6 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This retrospective case series described 4 Portuguese patients with hereditary angioedema (HAE) who received lanadelumab for long-term prophylaxis under an early access program. All patients showed substantial reductions in acute attacks, improved disease control, and significant quality of life improvements after 10 to 25 months of treatment.
Before lanadelumab, patients had severe disease with a mean of 23.5 acute attacks in the previous year and poor disease control (mean AECT score 3.25). After 10 to 25 months of lanadelumab therapy, all patients experienced a mean reduction in acute attacks of 94.75%, with individual reductions ranging from 90% to 100%. Disease control improved, with mean AECT scores increasing to 13.75 (all >10). Quality of life also improved significantly, with mean AE-QoL scores decreasing from 41.25 to 5.75 points, achieving a minimal clinically important difference in all patients. No severe adverse events were reported.
